To include your compound in the COVID-19 Resource Center, submit it here.

Daily Chart: More vaccine, therapeutic trial starts

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

BioCentury’s COVID-19 Resource Center is now tracking 624 therapeutics and vaccines in preclinical and clinical testing, up from last Monday’s 599 total.

In the past week, 20 additional therapeutics entered the clinic, bringing the total to 318.

Sichuan Clover Biopharmaceuticals Inc., Imperial College London and CureVac AG moved their vaccines into clinical testing, pushing the number of candidates in trials to 19 (see “Vaccines Enter the Clinic”; “House Lawmakers Call for Transparency”).

BioCentury’s program count also reflects the updated classification of two vaccines from Shenzhen Genoimmune Medical Institute as preclinical, rather than clinical. Although the trials are listed on, the institute told BioCentury the trial starts are pending approval from China’s Center for Drug Evaluation.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers